PT-141 Peptide (Bremelanotide)

One of the shelf's few molecules with a genuine FDA approval, label and all.

PT-141 is bremelanotide, a cyclic seven amino acid melanocortin receptor agonist that arose as a metabolite of Melanotan 2 and acts on central melanocortin pathways rather than on peripheral blood flow. It is FDA approved and marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

This one made it all the way. Full development, FDA approval in 2019, a real product name on a real pharmacy shelf, prescription only.

PT-141, bremelanotide if you're being formal, is a cyclic melanocortin agonist. Its family tree matters. It descends from melanotan-II, the tanning peptide, and here's the wrinkle: melanocortin receptors are five cousins in one group chat. Pigmentation, appetite and arousal signalling all read the same thread.

So a tanning project took a left turn and came out the other side as this. That's not a rumour. That's the development history.

We carry the 5mg vial, and the box of ten takes a quarter off the price.

An approved drug with a research-vial twin. The approval belongs to the pharmacy product. The label's warnings travel with the molecule either way.

Descended from a tanning peptide, and the family resemblance never left.

Melanocortin receptors come as a five-member family, and picking one cousin out of the group chat is the entire game.

PT-141 talks to the family broadly enough that its effects were never going to be single-purpose.

So does a blood pressure signal, transient increases documented well enough that the label limits how often the approved product can be used and rules it out for some cardiovascular histories.

Here's the honest part, and for once a regulator wrote it for us.

The label is the mechanism section with consequences attached. It's public, it's specific, and it's the one document about this compound that nobody selling it links to.

Approved, labelled, and the label is required reading.

A complete file, for once. Phase 1 through 3, an approval, and post-market surveillance running since 2019.

The trials put numbers on everything: modest efficacy against placebo, the blood pressure effect, the pigmentation risk, and nausea rates high enough to be a headline of their own. All quantified. All public.

The approval covers one specific indication, in one specific population, under prescription. A research vial inherits none of that. The molecule's documented risks come along regardless, because they're in the molecule, not the packaging.

We're not gonna dress it up. Approved isn't the same as benign. The label says both things at once, and it's three clicks away on the FDA's own site.

The rarest thing on this page isn't the compound. It's the paperwork.

Same day out of British Columbia. Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.

Then into the fridge. Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.

There is an approved label for this one. That is unusual here and it is worth using. It documents a transient blood pressure rise after each dose, contraindications in uncontrolled hypertension and known cardiovascular disease, and hyperpigmentation that may not resolve. Most compounds on this site have no such document to check.